{"id":67419,"date":"2026-06-05T13:49:44","date_gmt":"2026-06-05T05:49:44","guid":{"rendered":"https:\/\/flcube.com\/?p=67419"},"modified":"2026-06-05T13:49:45","modified_gmt":"2026-06-05T05:49:45","slug":"gilead-and-lakefront-complete-1-675b-acquisition-of-ouro-medicines-securing-bcmaxcd3-t-cell-engager-for-autoimmune-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67419","title":{"rendered":"Gilead and Lakefront Complete $1.675B Acquisition of Ouro Medicines \u2013 Securing BCMAxCD3 T Cell Engager for Autoimmune Diseases"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Gilead Sciences<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/GILD:NASDAQ\">NASDAQ: GILD<\/a>) and <strong>Lakefront Biotherapeutics NV<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/LKFT:NASDAQ\">NASDAQ: LKFT<\/a>) announced the successful completion of their acquisition of <strong>Ouro Medicines<\/strong>, securing <strong>gamgertamig (OM336)<\/strong>, a clinical-stage <strong>BCMAxCD3 T cell engager<\/strong> for autoimmune diseases.<\/p>\n\n\n\n<h2 id=\"h-transaction-details\" class=\"wp-block-heading\">Transaction Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirers<\/strong><\/td><td>Gilead Sciences and Lakefront Biotherapeutics (50\/50 partnership)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Ouro Medicines<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>Previously announced, completed 04 Jun 2026<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>USD 1,675 million (split equally between Gilead and Lakefront)<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Up to USD 500 million (shared equally)<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td>Up to USD 2,175 million<\/td><\/tr><tr><td><strong>Asset Acquired<\/strong><\/td><td>Gamgertamig (OM336) \u2013 BCMAxCD3 T cell engager<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-asset-profile-amp-clinical-development\" class=\"wp-block-heading\">Asset Profile &amp; Clinical Development<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Gamgertamig (OM336) \u2013 <strong>clinical-stage BCMAxCD3 T cell engager<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Enables <strong>rapid and deep plasma cell and B cell depletion<\/strong> through limited subcutaneous treatment course<\/li>\n\n\n\n<li><strong>Therapeutic Goal:<\/strong> Induce <strong>durable disease control<\/strong> in severe antibody-mediated orphan diseases<\/li>\n\n\n\n<li><strong>Target Indications:<\/strong><\/li>\n\n\n\n<li><strong>Autoimmune hemolytic anemia (AIHA)<\/strong><\/li>\n\n\n\n<li><strong>Immune thrombocytopenia (ITP)<\/strong><\/li>\n\n\n\n<li><strong>Regulatory Status:<\/strong> Granted both <strong>Fast Track<\/strong> and <strong>Orphan Drug Designation<\/strong> by U.S. FDA for AIHA and ITP<\/li>\n\n\n\n<li><strong>Development Timeline:<\/strong> Expected to enter <strong>registrational studies as early as 2027<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-portfolio-integration\" class=\"wp-block-heading\">Strategic Portfolio Integration<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Strategic Rationale<\/th><\/tr><\/thead><tbody><tr><td><strong>Gilead Sciences<\/strong><\/td><td>Adds gamgertamig to growing <strong>inflammation portfolio<\/strong>, expanding beyond traditional antiviral and oncology focus into autoimmune diseases<\/td><\/tr><tr><td><strong>Lakefront Biotherapeutics<\/strong><\/td><td>Establishes <strong>foundation of clinical development pipeline<\/strong> with high-value asset in orphan autoimmune indications<\/td><\/tr><tr><td><strong>Shared Development<\/strong><\/td><td>Leverages complementary expertise: Gilead&#8217;s commercial infrastructure and Lakefront&#8217;s specialized development capabilities<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-opportunity-analysis\" class=\"wp-block-heading\">Market Opportunity Analysis<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Market Characteristics<\/th><\/tr><\/thead><tbody><tr><td><strong>Autoimmune Hemolytic Anemia (AIHA)<\/strong><\/td><td>Rare orphan disease affecting ~30,000 patients in US\/EU; limited treatment options; high unmet medical need<\/td><\/tr><tr><td><strong>Immune Thrombocytopenia (ITP)<\/strong><\/td><td>Affects ~100,000 patients in US alone; current treatments include corticosteroids, splenectomy, and expensive biologics<\/td><\/tr><tr><td><strong>Commercial Potential<\/strong><\/td><td>Peak annual sales projected at $800 million-$1.2 billion globally across both indications<\/td><\/tr><tr><td><strong>Pricing Power<\/strong><\/td><td>Orphan drug designation supports premium pricing; potential for curative-like durable responses justifies high value proposition<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>First BCMAxCD3 T cell engager in autoimmune space; significant differentiation from existing immunosuppressive therapies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-financial-amp-strategic-implications\" class=\"wp-block-heading\">Financial &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Risk Sharing Model:<\/strong> 50\/50 cost and milestone structure reduces individual company exposure while maintaining full strategic optionality<\/li>\n\n\n\n<li><strong>R&amp;D Efficiency:<\/strong> Shared development costs accelerate timeline to registrational studies<\/li>\n\n\n\n<li><strong>Commercial Rights:<\/strong> Terms undisclosed, but likely structured to align with each company&#8217;s geographic strengths<\/li>\n\n\n\n<li><strong>Pipeline Validation:<\/strong> Demonstrates confidence in T cell engager platform extension beyond oncology into autoimmune diseases<\/li>\n\n\n\n<li><strong>Investor Impact:<\/strong> Modest near-term financial impact offset by long-term pipeline diversification benefits<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding acquisition completion, clinical development timelines, regulatory designations, and commercial expectations for gamgertamig. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gilead Sciences (NASDAQ: GILD) and Lakefront Biotherapeutics NV (NASDAQ: LKFT) announced the successful completion of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[226,4775,1025,4776],"class_list":["post-67419","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-gilead-sciences","tag-lakefront-biotherapeutics","tag-nasdaq-gild","tag-nasdaq-lkft"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Gilead and Lakefront Complete $1.675B Acquisition of Ouro Medicines \u2013 Securing BCMAxCD3 T Cell Engager for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Gilead Sciences (NASDAQ: GILD) and Lakefront Biotherapeutics NV (NASDAQ: LKFT) announced the successful completion of their acquisition of Ouro Medicines, securing gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager for autoimmune diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67419\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead and Lakefront Complete $1.675B Acquisition of Ouro Medicines \u2013 Securing BCMAxCD3 T Cell Engager for Autoimmune Diseases\" \/>\n<meta property=\"og:description\" content=\"Gilead Sciences (NASDAQ: GILD) and Lakefront Biotherapeutics NV (NASDAQ: LKFT) announced the successful completion of their acquisition of Ouro Medicines, securing gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager for autoimmune diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67419\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-05T05:49:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-05T05:49:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67419#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67419\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Gilead and Lakefront Complete $1.675B Acquisition of Ouro Medicines \u2013 Securing BCMAxCD3 T Cell Engager for Autoimmune Diseases\",\"datePublished\":\"2026-06-05T05:49:44+00:00\",\"dateModified\":\"2026-06-05T05:49:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67419\"},\"wordCount\":436,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Gilead Sciences\",\"Lakefront Biotherapeutics\",\"NASDAQ: GILD\",\"NASDAQ: LKFT\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67419#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67419\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67419\",\"name\":\"Gilead and Lakefront Complete $1.675B Acquisition of Ouro Medicines \u2013 Securing BCMAxCD3 T Cell Engager for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-05T05:49:44+00:00\",\"dateModified\":\"2026-06-05T05:49:45+00:00\",\"description\":\"Gilead Sciences (NASDAQ: GILD) and Lakefront Biotherapeutics NV (NASDAQ: LKFT) announced the successful completion of their acquisition of Ouro Medicines, securing gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager for autoimmune diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67419#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67419\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67419#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead and Lakefront Complete $1.675B Acquisition of Ouro Medicines \u2013 Securing BCMAxCD3 T Cell Engager for Autoimmune Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gilead and Lakefront Complete $1.675B Acquisition of Ouro Medicines \u2013 Securing BCMAxCD3 T Cell Engager for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry","description":"Gilead Sciences (NASDAQ: GILD) and Lakefront Biotherapeutics NV (NASDAQ: LKFT) announced the successful completion of their acquisition of Ouro Medicines, securing gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager for autoimmune diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67419","og_locale":"en_US","og_type":"article","og_title":"Gilead and Lakefront Complete $1.675B Acquisition of Ouro Medicines \u2013 Securing BCMAxCD3 T Cell Engager for Autoimmune Diseases","og_description":"Gilead Sciences (NASDAQ: GILD) and Lakefront Biotherapeutics NV (NASDAQ: LKFT) announced the successful completion of their acquisition of Ouro Medicines, securing gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager for autoimmune diseases.","og_url":"https:\/\/flcube.com\/?p=67419","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-05T05:49:44+00:00","article_modified_time":"2026-06-05T05:49:45+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67419#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67419"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Gilead and Lakefront Complete $1.675B Acquisition of Ouro Medicines \u2013 Securing BCMAxCD3 T Cell Engager for Autoimmune Diseases","datePublished":"2026-06-05T05:49:44+00:00","dateModified":"2026-06-05T05:49:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67419"},"wordCount":436,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Gilead Sciences","Lakefront Biotherapeutics","NASDAQ: GILD","NASDAQ: LKFT"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67419#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67419","url":"https:\/\/flcube.com\/?p=67419","name":"Gilead and Lakefront Complete $1.675B Acquisition of Ouro Medicines \u2013 Securing BCMAxCD3 T Cell Engager for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-05T05:49:44+00:00","dateModified":"2026-06-05T05:49:45+00:00","description":"Gilead Sciences (NASDAQ: GILD) and Lakefront Biotherapeutics NV (NASDAQ: LKFT) announced the successful completion of their acquisition of Ouro Medicines, securing gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager for autoimmune diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67419#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67419"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67419#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Gilead and Lakefront Complete $1.675B Acquisition of Ouro Medicines \u2013 Securing BCMAxCD3 T Cell Engager for Autoimmune Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67419","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67419"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67419\/revisions"}],"predecessor-version":[{"id":67423,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67419\/revisions\/67423"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67419"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67419"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67419"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}